Statistical Methods In Drug Combination Studies
Download Statistical Methods In Drug Combination Studies full books in PDF, epub, and Kindle. Read online free Statistical Methods In Drug Combination Studies ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads.
Author |
: Wei Zhao |
Publisher |
: CRC Press |
Total Pages |
: 236 |
Release |
: 2014-12-19 |
ISBN-10 |
: 9781482216752 |
ISBN-13 |
: 1482216752 |
Rating |
: 4/5 (52 Downloads) |
Synopsis Statistical Methods in Drug Combination Studies by : Wei Zhao
The growing interest in using combination drugs to treat various complex diseases has spawned the development of many novel statistical methodologies. The theoretical development, coupled with advances in statistical computing, makes it possible to apply these emerging statistical methods in in vitro and in vivo drug combination assessments. Howeve
Author |
: Ming Tan |
Publisher |
: Wiley |
Total Pages |
: 0 |
Release |
: 2024-04-08 |
ISBN-10 |
: 0470669691 |
ISBN-13 |
: 9780470669693 |
Rating |
: 4/5 (91 Downloads) |
Synopsis Evaluating Synergy by : Ming Tan
Containing the historical and statistical information necessary to choose an analysis method and successful drug combination, Evaluating Synergy provides a systematic introduction of statistical methods for optimally designing and analyzing combination studies in cancer, anti-viral, and other therapeutic areas. This practical guide provides scientists in translational research, data analysts, and statisticians in cancer research with a detailed discussion on the challenging case of three or multi-drug combinations. Numerous examples accompany a presentation that illustrates experimental design considerations for modern drug analysis.
Author |
: Ronald J. Tallarida |
Publisher |
: CRC Press |
Total Pages |
: 268 |
Release |
: 2000-07-21 |
ISBN-10 |
: 9781420036107 |
ISBN-13 |
: 1420036106 |
Rating |
: 4/5 (07 Downloads) |
Synopsis Drug Synergism and Dose-Effect Data Analysis by : Ronald J. Tallarida
Not since this author's bestselling Manual of Pharmacologic Calculation has there been an available reference for drug data analysis. Incorporating the most relevant parts of that work, Drug Synergism and Dose-Effect Data Analysis focuses on drug combinations and all the quantitative analyses needed to analyze drug combination dose-effect data and to design experiments with two or more compounds. The book contains the statistical methods, the theory, and the computation algorithms needed to analyze single and combination drug data. Numerous examples accompany a presentation that illustrates the calculations and experimental design considerations for modern drug analysis.
Author |
: Mark Chang |
Publisher |
: CRC Press |
Total Pages |
: 362 |
Release |
: 2019-03-20 |
ISBN-10 |
: 9781351214537 |
ISBN-13 |
: 1351214535 |
Rating |
: 4/5 (37 Downloads) |
Synopsis Innovative Strategies, Statistical Solutions and Simulations for Modern Clinical Trials by : Mark Chang
"This is truly an outstanding book. [It] brings together all of the latest research in clinical trials methodology and how it can be applied to drug development.... Chang et al provide applications to industry-supported trials. This will allow statisticians in the industry community to take these methods seriously." Jay Herson, Johns Hopkins University The pharmaceutical industry's approach to drug discovery and development has rapidly transformed in the last decade from the more traditional Research and Development (R & D) approach to a more innovative approach in which strategies are employed to compress and optimize the clinical development plan and associated timelines. However, these strategies are generally being considered on an individual trial basis and not as part of a fully integrated overall development program. Such optimization at the trial level is somewhat near-sighted and does not ensure cost, time, or development efficiency of the overall program. This book seeks to address this imbalance by establishing a statistical framework for overall/global clinical development optimization and providing tactics and techniques to support such optimization, including clinical trial simulations. Provides a statistical framework for achieve global optimization in each phase of the drug development process. Describes specific techniques to support optimization including adaptive designs, precision medicine, survival-endpoints, dose finding and multiple testing. Gives practical approaches to handling missing data in clinical trials using SAS. Looks at key controversial issues from both a clinical and statistical perspective. Presents a generous number of case studies from multiple therapeutic areas that help motivate and illustrate the statistical methods introduced in the book. Puts great emphasis on software implementation of the statistical methods with multiple examples of software code (both SAS and R). It is important for statisticians to possess a deep knowledge of the drug development process beyond statistical considerations. For these reasons, this book incorporates both statistical and "clinical/medical" perspectives.
Author |
: John O'Quigley |
Publisher |
: CRC Press |
Total Pages |
: 390 |
Release |
: 2017-04-27 |
ISBN-10 |
: 9781351648028 |
ISBN-13 |
: 1351648020 |
Rating |
: 4/5 (28 Downloads) |
Synopsis Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials by : John O'Quigley
Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials gives a thorough presentation of state-of-the-art methods for early phase clinical trials. The methodology of clinical trials has advanced greatly over the last 20 years and, arguably, nowhere greater than that of early phase studies. The need to accelerate drug development in a rapidly evolving context of targeted therapies, immunotherapy, combination treatments and complex group structures has provided the stimulus to these advances. Typically, we deal with very small samples, sequential methods that need to be efficient, while, at the same time adhering to ethical principles due to the involvement of human subjects. Statistical inference is difficult since the standard techniques of maximum likelihood do not usually apply as a result of model misspecification and parameter estimates lying on the boundary of the parameter space. Bayesian methods play an important part in overcoming these difficulties, but nonetheless, require special consideration in this particular context. The purpose of this handbook is to provide an expanded summary of the field as it stands and also, through discussion, provide insights into the thinking of leaders in the field as to the potential developments of the years ahead. With this goal in mind we present: An introduction to the field for graduate students and novices A basis for more established researchers from which to build A collection of material for an advanced course in early phase clinical trials A comprehensive guide to available methodology for practicing statisticians on the design and analysis of dose-finding experiments An extensive guide for the multiple comparison and modeling (MCP-Mod) dose-finding approach, adaptive two-stage designs for dose finding, as well as dose–time–response models and multiple testing in the context of confirmatory dose-finding studies. John O’Quigley is a professor of mathematics and research director at the French National Institute for Health and Medical Research based at the Faculty of Mathematics, University Pierre and Marie Curie in Paris, France. He is author of Proportional Hazards Regression and has published extensively in the field of dose finding. Alexia Iasonos is an associate attending biostatistician at the Memorial Sloan Kettering Cancer Center in New York. She has over one hundred publications in the leading statistical and clinical journals on the methodology and design of early phase clinical trials. Dr. Iasonos has wide experience in the actual implementation of model based early phase trials and has given courses in scientific meetings internationally. Björn Bornkamp is a statistical methodologist at Novartis in Basel, Switzerland, researching and implementing dose-finding designs in Phase II clinical trials. He is one of the co-developers of the MCP-Mod methodology for dose finding and main author of the DoseFinding R package. He has published numerous papers on dose finding, nonlinear models and Bayesian statistics, and in 2013 won the Royal Statistical Society award for statistical excellence in the pharmaceutical industry.
Author |
: Shein-Chung Chow |
Publisher |
: CRC Press |
Total Pages |
: 412 |
Release |
: 2002-02-20 |
ISBN-10 |
: 0203910141 |
ISBN-13 |
: 9780203910146 |
Rating |
: 4/5 (41 Downloads) |
Synopsis Statistics in Drug Research by : Shein-Chung Chow
Emphasizing the role of good statistical practices (GSP) in drug research and formulation, this book outlines important statistics applications for each stage of pharmaceutical development to ensure the valid design, analysis, and assessment of drug products under investigation and establish the safety and efficacy of pharmaceutical compounds. Cove
Author |
: John O'Quigley |
Publisher |
: CRC Press |
Total Pages |
: 306 |
Release |
: 2017-04-27 |
ISBN-10 |
: 9781498746113 |
ISBN-13 |
: 149874611X |
Rating |
: 4/5 (13 Downloads) |
Synopsis Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials by : John O'Quigley
Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials gives a thorough presentation of state-of-the-art methods for early phase clinical trials. The methodology of clinical trials has advanced greatly over the last 20 years and, arguably, nowhere greater than that of early phase studies. The need to accelerate drug development in a rapidly evolving context of targeted therapies, immunotherapy, combination treatments and complex group structures has provided the stimulus to these advances. Typically, we deal with very small samples, sequential methods that need to be efficient, while, at the same time adhering to ethical principles due to the involvement of human subjects. Statistical inference is difficult since the standard techniques of maximum likelihood do not usually apply as a result of model misspecification and parameter estimates lying on the boundary of the parameter space. Bayesian methods play an important part in overcoming these difficulties, but nonetheless, require special consideration in this particular context. The purpose of this handbook is to provide an expanded summary of the field as it stands and also, through discussion, provide insights into the thinking of leaders in the field as to the potential developments of the years ahead. With this goal in mind we present: An introduction to the field for graduate students and novices A basis for more established researchers from which to build A collection of material for an advanced course in early phase clinical trials A comprehensive guide to available methodology for practicing statisticians on the design and analysis of dose-finding experiments An extensive guide for the multiple comparison and modeling (MCP-Mod) dose-finding approach, adaptive two-stage designs for dose finding, as well as dose–time–response models and multiple testing in the context of confirmatory dose-finding studies. John O’Quigley is a professor of mathematics and research director at the French National Institute for Health and Medical Research based at the Faculty of Mathematics, University Pierre and Marie Curie in Paris, France. He is author of Proportional Hazards Regression and has published extensively in the field of dose finding. Alexia Iasonos is an associate attending biostatistician at the Memorial Sloan Kettering Cancer Center in New York. She has over one hundred publications in the leading statistical and clinical journals on the methodology and design of early phase clinical trials. Dr. Iasonos has wide experience in the actual implementation of model based early phase trials and has given courses in scientific meetings internationally. Björn Bornkamp is a statistical methodologist at Novartis in Basel, Switzerland, researching and implementing dose-finding designs in Phase II clinical trials. He is one of the co-developers of the MCP-Mod methodology for dose finding and main author of the DoseFinding R package. He has published numerous papers on dose finding, nonlinear models and Bayesian statistics, and in 2013 won the Royal Statistical Society award for statistical excellence in the pharmaceutical industry.
Author |
: Institute of Medicine |
Publisher |
: National Academies Press |
Total Pages |
: 221 |
Release |
: 2001-01-01 |
ISBN-10 |
: 9780309171144 |
ISBN-13 |
: 0309171148 |
Rating |
: 4/5 (44 Downloads) |
Synopsis Small Clinical Trials by : Institute of Medicine
Clinical trials are used to elucidate the most appropriate preventive, diagnostic, or treatment options for individuals with a given medical condition. Perhaps the most essential feature of a clinical trial is that it aims to use results based on a limited sample of research participants to see if the intervention is safe and effective or if it is comparable to a comparison treatment. Sample size is a crucial component of any clinical trial. A trial with a small number of research participants is more prone to variability and carries a considerable risk of failing to demonstrate the effectiveness of a given intervention when one really is present. This may occur in phase I (safety and pharmacologic profiles), II (pilot efficacy evaluation), and III (extensive assessment of safety and efficacy) trials. Although phase I and II studies may have smaller sample sizes, they usually have adequate statistical power, which is the committee's definition of a "large" trial. Sometimes a trial with eight participants may have adequate statistical power, statistical power being the probability of rejecting the null hypothesis when the hypothesis is false. Small Clinical Trials assesses the current methodologies and the appropriate situations for the conduct of clinical trials with small sample sizes. This report assesses the published literature on various strategies such as (1) meta-analysis to combine disparate information from several studies including Bayesian techniques as in the confidence profile method and (2) other alternatives such as assessing therapeutic results in a single treated population (e.g., astronauts) by sequentially measuring whether the intervention is falling above or below a preestablished probability outcome range and meeting predesigned specifications as opposed to incremental improvement.
Author |
: Todd A. Durham |
Publisher |
: |
Total Pages |
: 226 |
Release |
: 2008-01-01 |
ISBN-10 |
: 0853697140 |
ISBN-13 |
: 9780853697145 |
Rating |
: 4/5 (40 Downloads) |
Synopsis Introduction to Statistics in Pharmaceutical Clinical Trials by : Todd A. Durham
All students of pharmaceutical sciences and clinical research need a solid knowledge and understanding of the nature, methods, application, and importance of statistics. Introduction to Statistics in Pharmaceutical Clinical Trials is an ideal introduction to statistics presented in the context of clinical trials conducted during pharmaceutical drug development. This novel approach both teaches the computational steps needed to conduct analyses and provides a conceptual understanding of how these analyses provide information that forms the rational basis for decision making throughout the drug development process.
Author |
: Harry Yang |
Publisher |
: CRC Press |
Total Pages |
: 251 |
Release |
: 2019-06-26 |
ISBN-10 |
: 9781351585934 |
ISBN-13 |
: 1351585932 |
Rating |
: 4/5 (34 Downloads) |
Synopsis Bayesian Analysis with R for Drug Development by : Harry Yang
Drug development is an iterative process. The recent publications of regulatory guidelines further entail a lifecycle approach. Blending data from disparate sources, the Bayesian approach provides a flexible framework for drug development. Despite its advantages, the uptake of Bayesian methodologies is lagging behind in the field of pharmaceutical development. Written specifically for pharmaceutical practitioners, Bayesian Analysis with R for Drug Development: Concepts, Algorithms, and Case Studies, describes a wide range of Bayesian applications to problems throughout pre-clinical, clinical, and Chemistry, Manufacturing, and Control (CMC) development. Authored by two seasoned statisticians in the pharmaceutical industry, the book provides detailed Bayesian solutions to a broad array of pharmaceutical problems. Features Provides a single source of information on Bayesian statistics for drug development Covers a wide spectrum of pre-clinical, clinical, and CMC topics Demonstrates proper Bayesian applications using real-life examples Includes easy-to-follow R code with Bayesian Markov Chain Monte Carlo performed in both JAGS and Stan Bayesian software platforms Offers sufficient background for each problem and detailed description of solutions suitable for practitioners with limited Bayesian knowledge Harry Yang, Ph.D., is Senior Director and Head of Statistical Sciences at AstraZeneca. He has 24 years of experience across all aspects of drug research and development and extensive global regulatory experiences. He has published 6 statistical books, 15 book chapters, and over 90 peer-reviewed papers on diverse scientific and statistical subjects, including 15 joint statistical works with Dr. Novick. He is a frequent invited speaker at national and international conferences. He also developed statistical courses and conducted training at the FDA and USP as well as Peking University. Steven Novick, Ph.D., is Director of Statistical Sciences at AstraZeneca. He has extensively contributed statistical methods to the biopharmaceutical literature. Novick is a skilled Bayesian computer programmer and is frequently invited to speak at conferences, having developed and taught courses in several areas, including drug-combination analysis and Bayesian methods in clinical areas. Novick served on IPAC-RS and has chaired several national statistical conferences.